News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Swiss Back Two-in-one GlaxoSmithKline Prostate Drug Duodart
March 22, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- A two-in-one prostate drug from GlaxoSmithKline (GSK.L) has won approval in Switzerland, its first European market, the British-based drugmaker said on Monday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
GlaxoSmithKline
MORE ON THIS TOPIC
Government
Fake Citations Plague RFK Jr.’s MAHA Report
May 30, 2025
·
2 min read
·
Tristan Manalac
Lung cancer
Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings
May 29, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Novo Opposes Pharma Tariffs, Urges Crackdown on Illicit Chinese Semaglutide
May 29, 2025
·
2 min read
·
Tristan Manalac
Drug pricing
Immuno-Oncology Stars Keytruda, Opdivo Likely To Come Into IRA Crosshairs
May 28, 2025
·
2 min read
·
Annalee Armstrong